An Update on Diabetes in the Community Pharmacy: Enhancing Patient Compliance through Counseling on Treatment and Delivery Devices

An Update on Diabetes in the Community Pharmacy: Enhancing Patient Compliance through Counseling on Treatment and Delivery Devices
Please read through the following information and click continue.

ACPE Universal Program Number: 207-000-07-122-H01-P
Release Date: October 13, 2007
Expiration Date: October 13, 2010

Statement of Need
The nation is facing a growing epidemic of diabetes. More than 20 million Americans have diabetes and 1.3 million new cases are diagnosed every year. A diagnosis of type 2 diabetes increases the risk of patients developing many serious complications, including cardiovascular disease, retinopathy, neuropathy and nephropathy. The direct and indirect costs of diabetes in 2002 were calculated at $132 billion, of which 80 percent was related to complications. Despite this growing number of patients diagnosed with type 2 diabetes initiation of insulin therapy is often delayed for more than eight years. The community pharmacist is in an ideal position to introduce patients to new products and delivery methods that are available to enhance patient outcomes. Pharmacists have frequent contact with patients and are critical in helping patients with type 2 diabetes manage their disease and accommodate their treatment to lifestyle issues.

Learning Objectives
Upon successful completion of this activity, the pharmacist should be better able to:

Discuss the potential health risks to a patient with type 2 diabetes in delaying the initiation of insulin therapy.

State the rationale for insulin therapy and its benefits in reducing the risk of diabetes related complications.

Discuss overcoming patient concerns to improve the successful implementation of insulin therapy at an appropriate time in the course of the patient’s disease.

Target Audience
The target audience for this program is pharmacists.

Instructions for Participation
To receive a certificate of completion that indicates your eligibility for continuing education credit, you must:

Review the content of the activity.

Successfully complete the post-test (16 out of 22 correct answers or higher).

You will have two (2) opportunities to successfully complete the activity.

Your statement of credit will be issued immediately upon successful completion of the post-test and submission of the evaluation.

Fee
There is no fee for this activity.

Accreditation
Pharmacists
ACPE logo NCPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program will provide 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit under the number 207-000-07-122-H01-P.

Faculty
Julie L. Olenak, PharmD (click on faculty name to view biography)
Assistant Professor, Department of Pharmacy Practice
Wilkes University
Wilkes-Barre, Pennsylvania

Disclosure Declaration
It is the policy of the National Community Pharmacists Association (NCPA) to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education program. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions) and drug delivery systems are subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Approval of credit for this continuing education activity does not imply endorsement by NCPA of any product or manufacturer identified.

Any medications or treatment methods suggested in this CE activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.

Commercial Support Statement
Commercial Support Provided by Pfizer.

Software Requirements

PC Windows 2000 Internet Explorer 5.5 or Firefox *Adobe Acrobat Reader	MAC Mac OS 10.2.8 Safari *Adobe Acrobat Reader
*REQUIRED TO VIEW PRINTABLE VERSION OF CE LESSON

Continue